Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need.  Their lead asset and stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI), and ischemic stroke. These product candidates are based on the company’s proprietary neural stem cell technology. Additionally, their lead small cell candidate, NSI-189, is a new chemical entity in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes, and stroke.

Contact Neuralstem
(301) 366-4960
Visit Website